Bausch + Lomb Raises 2026 Guidance Again as Vision '27 Plan Pays Off
Seeking Alpha · October 28, 2026
Key takeaways
- Bausch + Lomb raised 2026 revenue guidance to $5.450B-$5.550B and adjusted EBITDA guidance to $1.090B-$1.140B — its third guidance hike this year.
- Q3 2026 revenue hit $1.375 billion with 8% constant currency growth, 34% adjusted EBITDA growth, and its strongest free cash flow quarter since the 2022 IPO.
- All three segments — Pharmaceuticals (+11%), Surgical (+9%), and Vision Care (+6%) — grew, showing broad-based momentum from the Vision '27 strategic plan.
The Headline Numbers
Bausch + Lomb (BLCO) just bumped up its own 2026 forecast for the third time this year — a pretty strong signal that its turnaround plan, dubbed Vision '27, is working better than even the company expected. The eye-health giant now projects full-year revenue of $5.450 billion to $5.550 billion, with adjusted EBITDA landing between $1.090 billion and $1.140 billion.
That guidance bump came on the back of a genuinely strong Q3 2026. Revenue hit $1.375 billion for the quarter, up 8% in constant currency, while adjusted EBITDA jumped 34% year-over-year. Margins expanded to 23.6%, and free cash flow came in at $178 million — the company's best cash-generation quarter since its 2022 IPO.
Why Every Segment Is Pulling Its Weight
What stands out here isn't just one hot product line — it's that all three of Bausch + Lomb's business segments grew at once. Pharmaceuticals led the way at 11% growth, Surgical followed at 9%, and Vision Care rounded things out at 6%, all on a constant currency basis. For a company that's been working to prove it can execute consistently post-spinoff, broad-based growth like this is exactly the kind of proof point investors want to see.
Interim CEO Thomas Appio called this the fourth straight quarter of delivering on commitments made at the company's Investor Day — a streak that matters because it builds credibility for the Vision '27 strategic plan, the multi-year roadmap management laid out to grow revenue, expand margins, and strengthen the balance sheet.
What's Next: Project Elios
One storyline worth watching: Project Elios, a pipeline initiative currently under FDA review. Chief Medical Officer Yehia Hashad said the project remains on track, with the company still targeting FDA approval by the end of the year, assuming no new issues arise in the review process. An approval here could add another growth driver heading into 2027.
The Bigger Picture
Raising guidance three times in a single year isn't common, and it tells you management has more confidence in its forward visibility than it's shown in previous years. Combined with record cash generation, Bausch + Lomb looks like it's shifting from "story stock" to a company that's actually compounding results quarter after quarter.
Why it matters
For investors and anyone following eye-health and medtech stocks, repeated guidance raises signal real operational momentum, not just optimistic projections. It's a useful case study in how a post-spinoff company builds credibility through consistent execution.
Want deals on what you love?
Val finds local offers matched to your interests — free to start.
Meet Val